Tags

Type your tag names separated by a space and hit enter

Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013.
Commun Dis Intell Q Rep 2014; 38(4):E309-19CD

Abstract

From 1 January to 31 December 2013, around Australia 26 institutions around Australia participated in the Australian Staphylococcal Sepsis Outcome Programme (ASSOP). The aim of ASSOP 2013 was to determine the proportion of Staphylococcus aureus bacteraemia (SAB) isolates in Australia that are antimicrobial resistant, (with particular emphasis on susceptibility to methicillin) and to characterise the molecular epidemiology of the isolates. Overall 19.1% of the 2,010 SAB episodes were methicillin resistant, which is significantly higher than that reported in most European countries. Although the SAB 30-day all cause mortality appears to be decreasing in Australia, methicillin-resistant SAB associated mortality remains high (20.1%) and was significantly higher than methicillin-sensitive SAB associated mortality (13%) (P< 0.0001). With the exception of the β-lactams and erythromycin, antimicrobial resistance in methicillin sensitive S. aureus remains rare. However, in addition to the β-lactams, approximately 50% of methicillin-resistant S. aureus (MRSA) were resistant to erythromycin and ciprofloxacin and approximately 20% were resistant to co-trimoxazole, tetracycline and gentamicin. Linezolid, daptomycin and teicoplanin resistance was detected in a small number of S. aureus isolates. Resistance to vancomycin was not detected. Resistance was largely attributable to 2 healthcare associated MRSA clones; ST22-IV [2B] (EMRSA-15) and ST239-III [3A] (Aus-2/3 EMRSA). ST22-IV [2B] (EMRSA-15) has now become the predominant healthcare associated clone in Australia. Approximately 60% of methicillin-resistant SAB were due to community associated clones. Although polyclonal, almost 50% of community associated clones were characterised as ST93-IV [2B] (Queensland CA-MRSA) and ST1-IV [2B] (WA1). CA-MRSA, in particular the ST45-V [5C2&5] (WA84) clone, has acquired multiple antimicrobial resistance determinants including ciprofloxacin, erythromycin, clindamycin, gentamicin and tetracycline. As CA-MRSA is well established in the Australian community, it is important antimicrobial resistance patterns in community and healthcare associated SAB is monitored as this information will guide therapeutic practices in treating S. aureus sepsis.

Authors+Show Affiliations

Australian Collaborating Centre for Enterococcus and Staphylococcus Species (ACCESS) Typing and Research, School of Biomedical Sciences, Curtin University, Perth, Western Australia and Department of Microbiology and Infectious Diseases, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Western Australia.Division of Microbiology, Pathology Queensland Central Laboratory, Queensland and Griffith University School of Medicine, Gold Coast, Queensland.Australian Group on Antimicrobial Resistance, Royal Perth Hospital, Perth, Western Australia.Australian Collaborating Centre for Enterococcus and Staphylococcus Species (ACCESS) Typing and Research, School of Biomedical Sciences, Curtin University, Perth, Western Australia.Department of Microbiology and Infectious Diseases, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Western Australia.Department of Microbiology and Infectious Diseases, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Western Australia.Australian Collaborating Centre for Enterococcus and Staphylococcus Species (ACCESS) Typing and Research, School of Biomedical Sciences, Curtin University, Perth, Western Australia and Department of Microbiology and Infectious Diseases, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Western Australia.Department of Microbiology and Infectious Diseases, The Canberra Hospital, Australian Capital Territory and School of Clinical Medicine, Australian National University, Australian Capital Territory.School of Public Health and Community Medicine, UNSW Medicine, UNSW Australia, New South Wales.SA Pathology, Department of Microbiology and Infectious Diseases, Women's and Children's Hospital, North Adelaide, South Australia and Departments of Pathology, Paediatrics and Molecular and Biomedical Sciences, University of Adelaide, Adelaide, South Australia.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25631593

Citation

Coombs, Geoffrey W., et al. "Australian Staphylococcus Aureus Sepsis Outcome Programme Annual Report, 2013." Communicable Diseases Intelligence Quarterly Report, vol. 38, no. 4, 2014, pp. E309-19.
Coombs GW, Nimmo GR, Daly DA, et al. Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013. Commun Dis Intell Q Rep. 2014;38(4):E309-19.
Coombs, G. W., Nimmo, G. R., Daly, D. A., Le, T. T., Pearson, J. C., Tan, H. L., ... Turnidge, J. D. (2014). Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013. Communicable Diseases Intelligence Quarterly Report, 38(4), pp. E309-19.
Coombs GW, et al. Australian Staphylococcus Aureus Sepsis Outcome Programme Annual Report, 2013. Commun Dis Intell Q Rep. 2014 Dec 31;38(4):E309-19. PubMed PMID: 25631593.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013. AU - Coombs,Geoffrey W, AU - Nimmo,Graeme R, AU - Daly,Denise A, AU - Le,Tam T, AU - Pearson,Julie C, AU - Tan,Hui-Leen, AU - Robinson,James O, AU - Collignon,Peter J, AU - McLaws,Mary-Louise, AU - Turnidge,John D, AU - ,, Y1 - 2014/12/31/ PY - 2015/1/30/entrez PY - 2015/1/30/pubmed PY - 2015/10/1/medline SP - E309 EP - 19 JF - Communicable diseases intelligence quarterly report JO - Commun Dis Intell Q Rep VL - 38 IS - 4 N2 - From 1 January to 31 December 2013, around Australia 26 institutions around Australia participated in the Australian Staphylococcal Sepsis Outcome Programme (ASSOP). The aim of ASSOP 2013 was to determine the proportion of Staphylococcus aureus bacteraemia (SAB) isolates in Australia that are antimicrobial resistant, (with particular emphasis on susceptibility to methicillin) and to characterise the molecular epidemiology of the isolates. Overall 19.1% of the 2,010 SAB episodes were methicillin resistant, which is significantly higher than that reported in most European countries. Although the SAB 30-day all cause mortality appears to be decreasing in Australia, methicillin-resistant SAB associated mortality remains high (20.1%) and was significantly higher than methicillin-sensitive SAB associated mortality (13%) (P< 0.0001). With the exception of the β-lactams and erythromycin, antimicrobial resistance in methicillin sensitive S. aureus remains rare. However, in addition to the β-lactams, approximately 50% of methicillin-resistant S. aureus (MRSA) were resistant to erythromycin and ciprofloxacin and approximately 20% were resistant to co-trimoxazole, tetracycline and gentamicin. Linezolid, daptomycin and teicoplanin resistance was detected in a small number of S. aureus isolates. Resistance to vancomycin was not detected. Resistance was largely attributable to 2 healthcare associated MRSA clones; ST22-IV [2B] (EMRSA-15) and ST239-III [3A] (Aus-2/3 EMRSA). ST22-IV [2B] (EMRSA-15) has now become the predominant healthcare associated clone in Australia. Approximately 60% of methicillin-resistant SAB were due to community associated clones. Although polyclonal, almost 50% of community associated clones were characterised as ST93-IV [2B] (Queensland CA-MRSA) and ST1-IV [2B] (WA1). CA-MRSA, in particular the ST45-V [5C2&5] (WA84) clone, has acquired multiple antimicrobial resistance determinants including ciprofloxacin, erythromycin, clindamycin, gentamicin and tetracycline. As CA-MRSA is well established in the Australian community, it is important antimicrobial resistance patterns in community and healthcare associated SAB is monitored as this information will guide therapeutic practices in treating S. aureus sepsis. SN - 1445-4866 UR - https://www.unboundmedicine.com/medline/citation/25631593/Australian_Staphylococcus_aureus_Sepsis_Outcome_Programme_annual_report_2013_ L2 - http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3804g.htm DB - PRIME DP - Unbound Medicine ER -